KZA 0.00% 8.0¢ kazia therapeutics limited

DIPG Panel Discussion

  1. 114 Posts.
    lightbulb Created with Sketch. 125
    https://m-vest.com/insights/exclusive/exploring-new-targets-for-pediatric-brain-cancer

    Panel discussion with James Garner, Dr Josh Allen, Chief Medical Officer of Chimerix Inc, and Professor Sabine Mueller, the lead investigator in the PNOC multi-drug phase II study in DIPG and diffuse midline glioma, to discuss the latest developments in this area.

    Sign-up to website is required (but easy).
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.